. 2020 Apr 7;20(9):2356–2365. doi: 10.1111/ajt.15851

TABLE 1.

Endoglycosidase of Streptococcus pyogenes (EndoS)‐imlifidase allows hematopoietic chimerism in presensitized recipients

Treatment group	Engraftment ^a	Chimerism levels ^e
Not primed
Bortezomib and cyclophosphamide (CyBor)	6/6 ^a	>90%
Primed
CyBor	0/7 ^b
CyBor‐EndoS‐imlifidase*	5/8 ^c	98%, 85%, 57%, 20%, 9%
Cy‐EndoS‐imlifidase	0/2 ^d
Bor‐EndoS‐imlifidase	0/3 ^d

See figure legend of Figure 4 for details of chimerism induction protocol.

^{^a}

Represents B6.H‐2^g7 (n = 2) and NOD recipients (n = 4).

^{^b}

Represents B6.H‐2^g7 (n = 2) and NOD recipients (n = 5).

^{^c}

Represents one B6.H‐2^g7 (n = 1) and NOD recipients (n = 7).

^{^d}

Represents NOD recipients.

^{^e}

Shown are chimerism levels at 4 wk post bone marrow transplantation.

P < .05 by two‐sided Fisher's exact test when compared to “CyBor” primed group.